First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology’s LB-100 to Enter Recurrent Malignant Brain Tumors
December 04, 2019 09:35 ET
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the National Cancer Institute (NCI) has enrolled the first two patients of a...